Orchestra BioMed Hldgs Azioni (NASDAQ: OBIO)

Ultime notizie per Orchestra BioMed Hldgs (NASDAQ:OBIO) Azioni

ORCHESTRA BIOMED HOLDINGS IN

Orchestra BioMed Hldgs

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Orchestra BioMed Holdings, Inc. - Ordinary Shares

Orchestra BioMed Holdings Inc

Goldman Sachs analyst David Roman initiates coverage on Beta Bionics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>) with a Neutral rating and announces Price Target of $16.

News

Price Target

Initiation

Analyst Ratings

BBNX

Goldman Sachs Initiates Coverage On Beta Bionics with Neutral Rating, Announces Price Target of $16

Citigroup analyst Tyler Radke maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Buy and raises the price target from $265 to $329.

VEEV

Citigroup Maintains Buy on Veeva Systems, Raises Price Target to $329

Donaldson Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DCI#NYSE">DCI</a>) today announced that its Board of Directors declared a regular cash dividend of 30.0 cents per share, an increase of 11.1% from the prior quarterly dividend of 27.0 cents per share. The dividend is payable June 30, 2025, to shareholders of record on June 16, 2025. Donaldson is a member of the S&amp;P High-Yield Dividend Aristocrats Index and calendar year 2024 marked the 29th consecutive year of annual dividend increases. The Company has paid a cash dividend every quarter for 69 years.

Dividends

Donaldson Company Increases Quarterly Cash Dividend From $0.27 To $0.30 Per Share

Tech giant NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://www.benzinga.com/general/social-media/24/03/37879478/humble-beginnings-like-nvidia-reddit-was-founded-inside-a-restaurant">was founded in a Denny's </a>restaurant by friends Jensen Huang, Chris Malachowsky and Curtis Priem.
Today, the company is worth more than 3 trillion and Huang is one of the richest people in the world.
What Happened: The connection between Denny's Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DENN#NASDAQ">DENN</a>) and Nvidia will remain a part of <a href="https://www.benzinga.com/general/entertainment/25/05/45482864/nvidias-jensen-huang-doesnt-want-you-to-order-a-shake-at-dennys-get-a-coke-he-says">the company's history, </a>with the company being founded at a restaurant location in California.
Huang also previously worked as a dishwasher, busboy and waiter at Denny's, with his LinkedIn <a href="https://www.linkedin.com/in/jenhsunhuang/">profile </a>famously listing his work experience at Denny's from 1978 to 1983 and his role as Founder and CEO of NVIDIA from 1993 to present.
While the two companies are historically connected, their stock performance over the last few decades is extremely different and disconnected.
Denny's stock, which went public in 1997, has fallen 45% in the last year, is down 64% over the last five years and is down over 50% since going public.
Nvidia stock, which<a href="https://www.benzinga.com/general/education/25/01/43140861/if-you-invested-1000-in-nvidia-stock-at-ipo-heres-how-much-youd-have-today-2"> went public in 1999</a>, is up 21% over the last year, up over 1,400% over the last five years and a top performer since going public with gains of over 334,000%.
With the increase in Nvidia's stock price, the wealth of Huang has also risen.
Today, the Nvidia CEO is the 12th richest person in the world worth $122 billion, as reported by <a href="https://www.bloomberg.com/billionaires/?sref=TBDibEcD">Bloomberg</a>. While Huang has a ways to go ($24 billion) to re-enter the top 10 list, he is worth significantly more than many people around the world and worth more than many companies.
In fact, Huang is now worth 604.9x Denny&#8217;s current market capitalization ($201.7 million), a multiple that could bring the connection between the two companies full circle.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45675006/nvidia-stock-has-significant-upside-as-ai-godfather-jensen-huang-delivers-another-robust-quarter">Nvidia Stock Has &#8216;Significant Upside&#8217; As AI &#8216;Godfather&#8217; Jensen Huang Delivers Another &#8216;Robust Quarter&#8217;</a>
Why It's Important: A company founded by friends inside a Denny's booth is now worth more than $3 trillion and the company's CEO is 604.9x richer than the value of the entire Denny's restaurant company.
Huang has often recalled the famous breakfast meeting with the other Nvidia co-founders that led to the company's creation.
&#8220;It had all the coffee you could drink and no one could chase you out,&#8221; Huang recalled of the Denny&#8217;s meeting.
The famous Denny&#8217;s location also paid tribute to its connections to the business launch, with a plaque unveiled in September 2023.
Huang&nbsp;<a href="https://blogs.nvidia.com/blog/nvidia-dennys-trillion/" target="_blank" rel="noreferrer noopener">visited&nbsp;</a>the Denny&#8217;s location in 2023 and recalled the famous meeting while speaking with Denny&#8217;s CEO&nbsp;Kelli Valade.
&#8220;Denny&#8217;s has taught me so many lessons,&#8221; Huang said.
The Nvidia co-founder recalled having his first job at a Denny&#8217;s in Portland when he was 15 years old.
&#8220;I was a dishwasher, I was a busboy, I waited tables. No one can carry more coffee cups than I can.&#8221;
Huang encouraged people to get their first job in the restaurant business.
&#8220;It teaches you humility, it teaches you hard work, it teaches you hospitality.&#8221;
The three co-founders dreamed up the idea of creating a chip that would help make 3D graphics realistic on personal computers.
The plaque reads &#8220;the booth that launched a $1 trillion company.&#8221;
A post on X<a href="https://www.benzinga.com/news/24/02/37299226/alexis-ohanian-says-jensen-huangs-trillion-dollar-nvidia-brainwave-at-dennys-is-better-than-his-bill" target="_blank" rel="noreferrer noopener">&nbsp;highlighted the connection&nbsp;</a>between Nvidia and Denny&#8217;s.
&#8220;Nvidia was founded during a breakfast meeting at Denny&#8217;s. Today, Nvidia makes more money in four hours than Denny&#8217;s makes in a year,&#8221; Jon Ehrlichman tweeted in February 2024.
<ul class="wp-block-list">
<li>You may not be a billionaire like Jensen Huang, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/25/05/45600269/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-66">check out five stocks flying under the radar that deserve your attention.</a></li>
</ul>
Photo: jamesonwu1972 on Shutterstock.com

Education

DENN

NVDA

Jensen Huang Founded Nvidia At A Denny's, Now He's Worth 600x More Than The Restaurant Chain

Citigroup analyst Andrew Kaplowitz maintains 3M (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) with a Neutral and raises the price target from $141 to $160.

Citigroup Maintains Neutral on 3M, Raises Price Target to $160

<a href="https://www.youtube.com/watch?v=bdx14Y22w90" title="https://www.youtube.com/watch?v=bdx14Y22w90">https://www.youtube.com/watch?v=bdx14Y22w90</a>

Macro Economic Events

Politics

Economics

General

President Trump, Elon Musk Hold News Conference At White House; Elon Musk Says Not End Of DOGE; DOGE Team Will Grow Stronger; I'll Continue To Be Visiting; Will Be A Friend And Adviser To President Trump

Goldman Sachs analyst David Roman initiates coverage on Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Buy rating and announces Price Target of $380.

PODD

Goldman Sachs Initiates Coverage On Insulet with Buy Rating, Announces Price Target of $380

Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) on Friday shared safety and efficacy results from the open-label Phase 1 KANDLELIT-001 study of MK-1084 alone and in combination <a href="https://www.benzinga.com/general/health-care">with other therapies</a>. 
The study included patients with KRAS G12C-mutant solid tumors, advanced colorectal cancer (CRC) and <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">non-small cell lung cancer (NSCLC)</a>.
In patients with advanced&nbsp;KRAS&nbsp;G12C-mutated CRC and NSCLC, MK-1084, either as monotherapy or in combinations, demonstrated a manageable safety profile and antitumor activity.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45450568/merck-says-blockbuster-keytruda-based-regimen-can-help-certain-ovarian-cancer-patients-live-longer" rel="noreferrer noopener">Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda</a>
In CRC, the study assessed MK-1084 as monotherapy, as well as in combination with cetuximab with or without chemotherapy (oxaliplatin and leucovorin plus 5-fluorouracil [mFOLFOX6]). The study evaluated the overall response rate (ORR) in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45691989/merck-announces-mk-1084-an-investigational-kras-g12c-inhibitor-shows-antitumor-activity-in-phase-1" rel="noreferrer noopener">previously treated patients</a>:
<ul class="wp-block-list">
<li>MK-1084 monotherapy (N=53)- Confirmed ORR of 38% and unconfirmed ORR of 43%.</li>
<li>MK-1084 + cetuximab (N=39)-Confirmed ORR of 46% and unconfirmed ORR of 56%.</li>
<li>MK-1084 + cetuximab + mFOLFOX6 (N=29)-Confirmed ORR of 38% and unconfirmed ORR of 66%.</li>
</ul>
In addition to KANDLELIT-001, MK-1084 will be investigated in:
<ul class="wp-block-list">
<li>Phase 3 KANDLELIT-012 study, which is investigating MK-1084 in combination with cetuximab and mFOLFOX6 for the first-line treatment of certain patients with locally advanced unresectable or metastatic CRC who have&nbsp;KRAS&nbsp;G12C-mutated tumors.</li>
<li>Phase 3 KANDLELIT-004 study, which is investigating MK-1084 in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic NSCLC who have&nbsp;KRAS&nbsp;G12C-mutated tumors and express PD-L1 (TPS ≥50%).</li>
</ul>
Concurrently, Merck announced results from the dose confirmation portion of the Phase 2/3 waveLINE-003 study of zilovertamab vedotin in combination with standard-of-care rituximab and gemcitabine-oxaliplatin (R-GemOx) for relapsed or refractory diffuse <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45691829/mercks-investigational-zilovertamab-vedotin-at-1-75-mgkg-dose-plus-standard-of-care-showed-promisi" rel="noreferrer noopener">large B-cell lymphoma (DLBCL)</a>.
At a pre-planned analysis, zilovertamab vedotin 1.75 mg/kg in combination with R-GemOx achieved a 56.3% objective response rate (ORR) in patients with relapsed or refractory DLBCL (n=16), with eight complete responses (CR) and one partial response (PR).
At a median follow-up of 18.1 months in patients receiving the 1.5 mg/kg dose of zilovertamab vedotin (n=15), ORR was 26.7% (3 CR [20.0%], 1 PR [6.7%]) and median DOR was 14.4 months.
At a median follow-up of 9.3 months for patients receiving the 2.0 mg/kg dose (n=7), the ORR was 57.1% (3 CR [42.9%], 1 PR [14.3%]) and median DOR was not reached.
Seven dose-limiting toxicities occurred across all participants.
Based on these results and accompanying safety data, the recommended Phase 2 dose of zilovertamab vedotin was determined to be 1.75 mg/kg when used with R-GemOx.
Price Action: MRK stock is up 1.09% at $77.24 at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/05/45697337/totalenergies-rge-jv-gets-green-light-to-import-renewable-power-to-singapore" target="_blank" rel="noreferrer noopener">TotalEnergies, RGE JV Gets Green Light To Import Renewable Power To Singapore</a></li>
</ul>
Image: Shutterstock

Health Care

Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers

Citigroup analyst Tyler Radke maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Neutral and lowers the price target from $320 to $295.

Citigroup Maintains Neutral on Salesforce, Lowers Price Target to $295

Citigroup analyst Ariel Rosa maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Buy and raises the price target from $288 to $317.

SAIA

Citigroup Maintains Buy on Saia, Raises Price Target to $317

<a href="https://asia.nikkei.com/Economy/Trade-war/Trump-tariffs/Japan-US-agree-to-another-round-of-tariff-talks-before-June-G7-summit">https://asia.nikkei.com/Economy/Trade-war/Trump-tariffs/Japan-US-agree-to-another-round-of-tariff-talks-before-June-G7-summit</a>

'Japan, US agree to another round of tariff talks before June G7 summit'- Nikkei Asia

WIIM

MULN

Mullen Automotive shares are trading lower on continued weakness after the company recently announced a 1-for-100 reverse stock split.

Morgan Stanley analyst Stephen Grambling maintains DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Overweight and lowers the price target from $53 to $51.

DKNG

Morgan Stanley Maintains Overweight on DraftKings, Lowers Price Target to $51

<a href="https://www.youtube.com/watch?v=bdx14Y22w90">https://www.youtube.com/watch?v=bdx14Y22w90</a>
&nbsp;

President Trump, Elon Musk Hold News Conference At White House; President Trump Says Many DOGE People Are Staying On; Musk Will Be Back And Forth

Morgan Stanley analyst Simeon Gutman maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Overweight and raises the price target from $1150 to $1225.

COST

Morgan Stanley Maintains Overweight on Costco Wholesale, Raises Price Target to $1225

On a recent <a href="https://www.youtube.com/watch?v=r63cwSWbFME">episode</a> of &#8220;The Joe Rogan Experience,&#8221; British comedian Jimmy Carr joined Joe Rogan for a wide-ranging conversation that took a serious turn when they began talking about corporate greed, education, and the crushing weight of student debt in the U.S.
<h2 class="wp-block-heading">Rogan And Carr Criticize The Student Loan System</h2>
Rogan didn't hold back when discussing the way student loans trap young people. "It's the one debt you cannot absolve in America even with bankruptcy," he said. "It's a scam. It's the dirtiest thing ever."
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Carr agreed and argued that the U.S. and U.K. should cancel student debt altogether. "We mis-sold people some bullsh&#x2A;t degrees," he said. "You're taking those people that took a chance and they went to university and they gave their time and they studied hard &#8230; and then they can't buy a house because &#8230; [their degree is] not in a STEM subject, it's in the <a href="https://www.benzinga.com/news/24/02/37305015/mark-cuban-says-liberal-arts-degrees-arent-ridiculous-anymore-in-the-age-of-ai-heres-why">humanities or something</a>, and they don't get the lifestyle they worked hard for."
Carr also pointed out that while socialism is often treated like a dirty word, most people <a href="https://www.benzinga.com/news/25/03/44532343/joe-rogan-says-social-safety-nets-are-very-important-for-people-he-calls-the-bootstraps-mentality-horsesht">accept its role in essential services</a> like fire departments and public schools. "Everyone agrees, right?" he said. "If your house burns down, we're going to have a fire service. It's not like, ‘Oh, we don't take care of that.'"
Rogan added that corporations <a href="https://www.benzinga.com/personal-finance/24/08/40133472/joe-rogan-tells-ceos-life-is-short-youre-wasting-all-your-time-trying-to-squeeze-as-much-money-a">rarely aim to do good</a> once they're public. "They never are satisfied," he said. "They never go, ‘Guys, we're doing great. If we just make this amount of money every year, like, that's wonderful. Let's just hang back. I think our profits are very high. Let's do good.'"
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
The two also talked about how student loans mostly burden middle- and working-class kids, locking them out of upward mobility. Carr described education as a social equalizer. "The opportunity to educate yourself and to do better is like—that's sort of part of the American Dream, isn't it?" he said.&nbsp;
Rogan agreed and noted that 18-year-olds often don't understand the long-term consequences of debt. "You're too young to be connected to a $50,000 debt when you're 18. You don't know what it means," he said. "The fact that it's going to follow you around forever and haunt you&#8230; I think it's evil."
See Also: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
<h2 class="wp-block-heading">Federal Collections Resume As Borrowers Struggle</h2>
Their discussion comes as the federal government <a href="https://www.benzinga.com/25/05/45214832/with-16-trillion-owed-by-427-million-student-loan-borrowers-federal-government-resumes-collections-after-5-years-as-delinquencies-reach-record-high-transunion-warns">resumes collections on defaulted loans</a> for the first time since 2020. The U.S. Department of Education <a href="https://www.ed.gov/about/news/press-release/us-department-of-education-begin-federal-student-loan-collections-other-actions-help-borrowers-get-back-repayment">reports</a> that 42.7 million borrowers owe over $1.6 trillion in federal student debt. Only about one-third of those borrowers are currently making regular payments.&nbsp;
According to a <a href="https://newsroom.transunion.com/may-2025-student-loan-update/">TransUnion</a> report earlier this month, 20.5% of borrowers with payments due were more than 90 days late as of February. That's nearly double the 11.5% delinquency rate from February 2020 before pandemic relief began. Borrowers who defaulted saw their credit scores drop by an average of 63 points, with some super prime borrowers losing as much as 175 points. Experts warn this could make it harder to get loans, buy homes, or even rent.
Read Next: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a>
Image: Shutterstock

Joe Rogan Calls Student Loans A Scam 'You Cannot Absolve Even With Bankruptcy.' Says 'It's The Dirtiest Thing Ever'

ALZN

Alzamend Neuro shares are trading lower. The stock appears to be pulling back after surging on Thursday following a AL001 trial dosing update.

UiPath, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) &nbsp;shares are trading higher after the company reported better-than-expected first-quarter results, issued second-quarter sales guidance above estimates, <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">and raised its FY26 guidance</a>.
On Thursday, the company reported revenue of&nbsp;$356.62 million, versus&nbsp;estimates&nbsp;of $332.87 million, and adjusted EPS of&nbsp;11 cents, <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45683235/uipath-stock-surges-on-q1-earnings-beat-raised-guidance-this-was-a-milestone-quarter" rel="noreferrer noopener">exceeding the estimates of 10 cents</a>.
The company raised its fiscal 2026 forecast from a range of $1.52 billion to $1.53 billion to a new range of $1.549 billion to $1.554 billion versus <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">estimates of $1.53 billion</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/25/05/45687166/apple-may-see-fewer-searches-in-safari-but-google-ceo-sundar-pichai-insists-ai-is-fueling-overall-query-growth-far-from-a-zero-sum-game" rel="noreferrer noopener">Apple May See Fewer Searches In Safari, But Google CEO Sundar Pichai Insists AI Is Fueling Overall Query Growth: &#8216;Far From A Zero-Sum Game&#8217;</a>
Many analysts raised the price forecast on the <a target="_blank" href="https://www.benzinga.com/quote/PATH/analyst-ratings" rel="noreferrer noopener">stock following the results</a>.
RBC Capital analyst Matthew Hedberg maintained a Sector Perform rating and raised the price target from&nbsp;$13&nbsp;to&nbsp;$15.
After a challenging initial FY26 guide and miss to end last year due to public sector issues, UiPath showed encouraging progress in that vertical through proactive engagement, said the analyst.
According to the analyst, the Federal renewals met expectations, with some agencies even outperforming, though budget finalizations still present some pressure.
UiPath is seeing early success with agentic initiatives, including over 250,000 agent runs on Agent Builder and 11,000 process instances powered by Maestro since their preview releases, Hedberg remarked in an analyst note.
The analyst said that despite ongoing macroeconomic variability, management expressed continued prudence in their FY26 guidance, which was nonetheless raised across the board.
Hedberg highlighted the company&#8217;s optimism about its agentic AI opportunities and early customer interest, though significant revenue contributions from this area are not anticipated until FY27.
Needham analyst Scott Berg reiterated a Hold rating.
In an analyst note, Berg observed that UiPath posted a solid upside in revenue and operating income versus low Street expectations, primarily driven by strong license revenue that exceeded their estimate by 24%.
However, net new ARR came in at $27 million, a 39% year-over-year decrease (compared to a consensus of +$22.6 million), which the analyst attributes to lingering impacts from go-to-market (GTM) changes and execution improvements from FY25.
Berg pointed out that the current guidance indicates an increasingly second-half weighted performance, with 76% of net new ARR expected in the second half versus 57% in FY25, suggesting a moderately more challenging ramp-up.
The guidance comes despite continued declines in key metrics, including Net Revenue Retention (NRR), which dropped to 108% in the quarter, Berg added.
KeyBanc analyst Jason Celino retained a Sector Weight rating on the stock.
The analyst revised the FY26 estimates to account for the first quarter results and updated the outlook, expecting revenue of $1.552 billion (vs. $1.528 billion prior &amp; consensus of $1.522 billion) for FY26.
While the analyst finds the improved results and advancements within the public sector encouraging, he maintained the rating due to the early stage of the agentic AI opportunity and ongoing macroeconomic uncertainty.
Truist analyst Terry Tillman raised the price forecast from $12 to $13 while maintaining a Hold rating.
In an analyst note, Tillman underscored that the company surpassed their estimates, with particularly strong beats in total revenue and non-GAAP operating income.
Positive traction appears to be building from agentic solutions, the new partner program, and the recently acquired Peak, among other initiatives, which led the analyst to raise the estimates based on the improved outlook.
In particular, Tillman now sees revenue of $1.547 billion (vs. $1.527 billion earlier) compared to a consensus of $1.522 billion for FY26.
The analyst emphasized the company&#8217;s narrative is still a work in progress concerning the improvement of its annualized renewal run rate (ARR) and the return of net new ARR to a trajectory of robust growth.
Price Action: PATH shares are trading higher by 1.20% to $13.10 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45686378/openai-fights-to-keep-countersuit-alive-against-elon-musk-over-profit-shift-calls-his-974-billion-bid-a-media-stunt" target="_blank" rel="noreferrer noopener">OpenAI Wants Its Fraud And Media Manipulation Countersuit Against Elon Musk Kept Alive, Labels His $97.4 Billion Bid A Stunt</a></li>
</ul>
Photo by Ian Dewar Photography via Shutterstock

PATH

Analysts Applaud UiPath's AI Traction, But Net New ARR Slide Sparks Caution

Citigroup analyst Ariel Rosa maintains Knight-Swift (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) with a Buy and raises the price target from $48 to $53.

Citigroup Maintains Buy on Knight-Swift, Raises Price Target to $53

Reaching financial independence by 35 is the dream. At least, that's what <a href="https://www.benzinga.com/personal-finance/24/11/41781968/suze-orman-says-if-youre-rich-like-her-then-you-can-retire-early-but-if-you-only-have-2-million-">the FIRE community</a> would have you believe.
FIRE—short for Financial Independence, Retire Early—is a movement where people aggressively save, invest, and try to exit the rat race decades ahead of schedule. Skip the daily commute, skip the boss, and live life on your own terms.
But for one <a href="https://www.reddit.com/r/Fire/s/wy4GEfVf4t">user on Reddit's r/FIRE subreddit</a>, hitting every financial milestone didn't come with freedom. It came with burnout.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
He's 35, married with two kids, earns $250,000 a year in a high-stress corporate role, and runs a startup projected to earn $90,000. His net worth? <a href="https://www.benzinga.com/personal-finance/25/05/45585378/do-you-have-an-upper-class-nest-egg-heres-what-the-top-20-have-saved-for-retirement-hint-its-less-than-youd-think">Over $3 million</a>. That includes $2.5 million in brokerage accounts, $200,000 in retirement, $30,000 in cash, and a home worth $650,000—with only $300,000 left on the mortgage at 2.25%. Two cars are paid off, and the third is nearly there.
He's done it all right. And yet?
"I don't think I've ever been more miserable," he wrote.
"I feel dead inside and I don't like who I've become. I feel like I can't enjoy anything anymore, even hobbies I once really enjoyed. I can't recall the last time I was actually happy or honestly what that even really felt like."
He said he's losing sleep, spending hours staring at the ceiling, thinking about the years he's sacrificed. He goes through the motions, smiling for his family, pretending things are fine.
"If only one of us has to be miserable, it should be me. No need to bring them down too."
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
For a community obsessed with asset allocation and early retirement math, the response was strikingly emotional. Users didn't toss spreadsheets at him—they tossed support.
One person asked, "How did you get a $3 million portfolio in 13 years making $250K or less?"
Another replied, "Lots of risk is the answer."
Someone else said, "Sounds like OP is trading time and life experiences for money. And now found themselves entirely empty."
The thread turned quickly from admiration to intervention.
"You should probably talk to a mental health professional. Not a financial forum."
"Walk away from the corp job to focus on your startup for one year… Spend more time with the kids and wife."
"You can't get back those years of your youth. They're worth more than $250K a year."
See Also: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
And the harshest but most honest comment of all?
"If it makes you feel any better, I feel this way with almost $3 million less than you."
This entire crisis tracks with what psychologists call the hedonic treadmill—the idea that happiness levels may shift briefly after life changes but eventually drift back to a personal baseline. According to <a href="https://www.psychologytoday.com/us/basics/hedonic-treadmill">Psychology Today</a>, that baseline isn't the same for everyone, and a person can have different set points for emotional highs versus overall life satisfaction.
In other words, your life can look fantastic on paper and still feel emotionally bankrupt.
So maybe FIRE isn't the finish line after all. Maybe it's the starting line for a harder question: what are you really chasing? Because no amount of brokerage accounts or <a href="https://www.benzinga.com/money/smartasset">early retirement plans</a> will buy back your 30s—or the peace you expected to find once you got here.
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Personal Finance

35-Year-Old With $3 Million Net Worth Making $250K A Year Says Despite Hitting All Financial Goals, He's Miserable — 'I Feel Dead Inside'

Press Releases

Orchestra BioMed to Present at Upcoming Investor Conferences

Earnings

Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System

SmallCaps Gaining Momentum: TIVC, GELS, SLI, OBIO in Healthcare, Biotech, Energy, Military Defense, Etc. – More Stocks Inside

Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

Legal

Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

GELS

OBIO

PNPNF

PRSO

TIVC

Apyx Medical

Accuray

Anteris Technologies Global Corp. - Common Stock

Anteris Technologies

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

BioSig Technologies

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Orchestra BioMed Hldgs

Notizie

Ultime notizie per Orchestra BioMed Hldgs (NASDAQ:OBIO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO